Dezerv

Fund Overview

Fund Size

Fund Size

₹894 Cr

Expense Ratio

Expense Ratio

0.83%

ISIN

ISIN

INF277K019A3

Minimum SIP

Minimum SIP

₹1,000

Exit Load

Exit Load

No Charges

Inception Date

Inception Date

28 Dec 2015

About this fund

Tata India Pharma & Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by Tata Mutual Fund. This fund has been in existence for 8 years, 4 months and 22 days, having been launched on 28-Dec-15.
As of 17-May-24, it has a Net Asset Value (NAV) of ₹29.09, Assets Under Management (AUM) of 893.64 Crores, and an expense ratio of 0.83%.
  • Tata India Pharma & Healthcare Fund Direct Growth has given a CAGR return of 13.58% since inception.
  • The fund's asset allocation comprises around 97.69% in equities, 0.00% in debts, and 2.31% in cash & cash equivalents.
  • You can start investing in Tata India Pharma & Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+55.80%

+51.54% (Cat Avg.)

3 Years

+17.72%

+13.98% (Cat Avg.)

5 Years

+26.00%

+24.42% (Cat Avg.)

Since Inception

+13.58%

(Cat Avg.)

Portfolio Summaryas of 30th April 2024

Equity872.98 Cr97.69%
Others20.66 Cr2.31%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity120.81 Cr13.52%
Aurobindo Pharma LtdEquity85.47 Cr9.56%
Lupin LtdEquity83.98 Cr9.40%
Dr Reddy's Laboratories LtdEquity66.78 Cr7.47%
Cipla LtdEquity58.1 Cr6.50%
Zydus Lifesciences LtdEquity44.94 Cr5.03%
Divi's Laboratories LtdEquity42.01 Cr4.70%
Fortis Healthcare LtdEquity37.5 Cr4.20%
Apollo Hospitals Enterprise LtdEquity35.03 Cr3.92%
Alkem Laboratories LtdEquity33.95 Cr3.80%
FDC LtdEquity21.37 Cr2.39%
Medi Assist Healthcare Services LtdEquity21.34 Cr2.39%
Ajanta Pharma LtdEquity21.18 Cr2.37%
HealthCare Global Enterprises LtdEquity20.72 Cr2.32%
Ipca Laboratories LtdEquity19.08 Cr2.14%
Orchid Pharma LtdEquity18.88 Cr2.11%
Torrent Pharmaceuticals LtdEquity18.74 Cr2.10%
Cash / Net Current AssetCash16.28 Cr1.82%
Sanofi India LtdEquity15.96 Cr1.79%
Jupiter Life Line Hospitals LtdEquity13.13 Cr1.47%
Wockhardt LtdEquity10.96 Cr1.23%
Mankind Pharma LtdEquity9.8 Cr1.10%
Aster DM Healthcare Ltd Ordinary SharesEquity9.21 Cr1.03%
Indoco Remedies LtdEquity9.05 Cr1.01%
Piramal Pharma LtdEquity8.57 Cr0.96%
Medplus Health Services LtdEquity8.28 Cr0.93%
Procter & Gamble Health LtdEquity7.86 Cr0.88%
Syngene International LtdEquity7.38 Cr0.83%
Coromandel International LtdEquity7.25 Cr0.81%
Ami Organics LtdEquity6.15 Cr0.69%
GlaxoSmithKline Pharmaceuticals LtdEquity5.13 Cr0.57%
A) RepoCash - Repurchase Agreement4.39 Cr0.49%
Deepak Nitrite LtdEquity4.35 Cr0.49%

Allocation By Market Cap (Equity)

Large Cap Stocks

39.31%

Mid Cap Stocks

38.29%

Small Cap Stocks

20.09%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare855.23 Cr95.70%
Basic Materials17.75 Cr1.99%

Risk & Performance Ratios

Standard Deviation

This fund

14.25%

Cat. avg.

14.57%

Lower the better

Sharpe Ratio

This fund

0.87

Cat. avg.

0.69

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.16

Higher the better

Fund Managers

MS

Meeta Shetty

Since March 2021

Additional Scheme Detailsas of 30th April 2024

ISININF277K019A3Expense Ratio0.83%Exit LoadNo ChargesFund Size₹894 CrAge28 Dec 2015Lumpsum Minimum₹5,000Fund StatusOpen Ended Investment CompanyBenchmarkNifty Pharma TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Withdrawal within 1 year

Flat 15% tax on realised gains (STCG - short term capital gains)

Withdrawal after 1 year

10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)

Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Motilal Oswal S&P BSE Healthcare ETF

Very High Risk

0.2%-₹13.07 Cr54.0%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth

Very High Risk

1.0%1.0%₹694.50 Cr57.4%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹694.50 Cr55.3%
Aditya Birla Sun Life Nifty Healthcare ETF

Very High Risk

0.2%-₹36.50 Cr52.9%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.4%1.0%₹161.86 Cr48.4%
ITI Pharma and Healthcare Fund Regular Growth

Very High Risk

2.3%1.0%₹161.86 Cr45.4%
Mirae Asset Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹2236.01 Cr52.1%
Mirae Asset Healthcare Fund Regular Growth

Very High Risk

2.0%1.0%₹2236.01 Cr49.9%
Nippon India Nifty Pharma ETF

Very High Risk

0.2%-₹639.49 Cr53.9%
Axis NIFTY Healthcare ETF

Very High Risk

0.3%-₹16.41 Cr51.7%

About the AMC

Total AUM

₹1,43,432 Cr

Address

Mafatlal Centre, 9th Floor, Mumbai, 400 021

Other Funds by Tata Mutual Fund

Fund nameExpense RatioExit LoadFund size
1Y
Tata Silver ETF Fund of Fund Direct Growth

Very High Risk

0.1%0.0%₹31.76 Cr-
Tata Gold ETF Fund of Fund Direct Growth

High Risk

0.1%0.0%₹61.62 Cr-
Tata Fixed Maturity Plan Series 56 Scheme G Direct Growth

Low to Moderate Risk

-0.0%--
Tata Fixed Maturity Plan Series 56 Scheme H Direct Growth

Low to Moderate Risk

-0.0%--
Tata Fixed Maturity Series E Direct Growth

Low to Moderate Risk

-0.0%--
Tata Balanced Advantage Fund Direct Growth

High Risk

0.4%1.0%₹9107.02 Cr23.1%
Tata Ultra Short Term Fund Direct Growth

Low to Moderate Risk

0.4%0.0%₹2712.12 Cr7.6%
Tata Business Cycle Fund Direct Growth

Very High Risk

0.4%1.0%₹2200.75 Cr54.1%
Tata Nifty India Digital ETF Fund of Fund Direct Growth

Very High Risk

0.1%1.0%₹48.64 Cr44.2%
Tata Nifty SDL Plus AAA PSU Bond Dec 2027 60: 40 Index Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹846.83 Cr6.7%
Tata Floating Rate Fund Direct Growth

Low to Moderate Risk

0.3%0.0%₹219.91 Cr7.4%
Tata Small Cap Fund Direct Growth

Very High Risk

0.3%1.0%₹6951.59 Cr46.9%
Tata Large & Mid Cap Fund Direct Growth

Very High Risk

0.7%1.0%₹7203.51 Cr32.7%
Tata Mid Cap Growth Fund Direct Growth

Very High Risk

0.8%1.0%₹3637.33 Cr57.8%
Tata Hybrid Equity Fund Direct Growth

Very High Risk

1.0%1.0%₹3748.90 Cr24.2%
Tata Ethical Fund Direct Growth

Very High Risk

0.8%0.0%₹2489.80 Cr33.4%
Tata Gilt Securities Fund Direct Growth

Moderate Risk

0.4%0.0%₹764.20 Cr7.0%
Tata Equity P/E Fund Direct Growth

Very High Risk

0.8%1.0%₹7753.52 Cr50.8%
Tata Infrastructure Fund Direct Growth

Very High Risk

1.3%0.0%₹2064.50 Cr73.6%
Tata Treasury Advantage Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹2349.85 Cr7.3%
Tata Money Market Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹17287.51 Cr7.8%
Tata Equity Savings Fund Direct Growth

Moderately High risk

0.5%0.0%₹141.56 Cr16.6%
Tata Young Citizens Fund Direct Growth

Very High Risk

2.2%1.0%₹339.36 Cr29.5%
Tata Liquid Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹17257.17 Cr7.3%
Tata Large Cap Fund Direct Growth

Very High Risk

1.1%1.0%₹2103.32 Cr34.8%
Tata Retirement Savings Moderate Fund Direct Growth

Very High Risk

0.6%1.0%₹1977.17 Cr31.9%
Tata Retirement Savings Conservative Fund Direct Growth

Moderately High risk

1.0%1.0%₹165.87 Cr14.7%
Tata Short Term Bond Fund Direct Growth

Moderate Risk

0.4%0.0%₹2333.49 Cr7.0%
Tata Retirement Savings Progressive Fund Direct Growth

Very High Risk

0.6%1.0%₹1835.96 Cr38.2%
Tata Corporate Bond Fund Direct Growth

Moderate Risk

0.3%0.0%₹1105.85 Cr7.2%
Tata India Consumer Fund Direct Growth

Very High Risk

0.8%0.0%₹1949.56 Cr39.9%
Tata Digital India Fund Direct Growth

Very High Risk

0.4%0.0%₹9460.81 Cr36.0%
Tata Banking & Financial Services Fund Direct Growth

Very High Risk

0.5%0.0%₹2093.75 Cr23.5%
Tata Resources & Energy Fund Direct Growth

Very High Risk

0.8%0.0%₹593.80 Cr47.2%
Tata India Pharma & Healthcare Fund Direct Growth

Very High Risk

0.8%0.0%₹893.64 Cr55.8%
TATA Nifty G-SEC Dec 2029 Index Fund Direct Growth

Moderate Risk

0.1%0.0%₹169.84 Cr6.5%
Tata Multi Asset Opportunities Fund Direct Growth

Very High Risk

0.4%1.0%₹2754.79 Cr29.5%
Tata Flexi Cap Fund Direct Growth

Very High Risk

0.7%1.0%₹2751.38 Cr35.1%
Tata Dividend Yield Fund Direct Growth

Very High Risk

0.5%1.0%₹889.11 Cr44.8%
Tata Housing Opportunities Fund Direct Growth

Very High Risk

0.7%1.0%₹565.65 Cr39.5%
Tata Arbitrage Fund Direct Growth

Low Risk

0.3%0.0%₹11605.73 Cr8.4%
Tata Banking & PSU Debt Fund Direct Growth

Moderate Risk

0.3%0.0%₹213.01 Cr6.9%
Tata Overnight Fund Direct Growth

Low Risk

0.1%0.0%₹3181.71 Cr6.8%
Tata Nifty Midcap 150 Momentum 50 Index Fund Direct Growth

Very High Risk

0.3%0.0%₹258.60 Cr75.1%
Tata CRISIL IBX Gilt Index-April 2026 Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹1102.39 Cr6.6%
Tata Multicap Fund Direct Growth

Very High Risk

0.3%1.0%₹2933.77 Cr31.3%
Tata Treasury Advantage Fund Segregated Portfolio 1 Direct Growth

Low to Moderate Risk

-0.0%-154.6%
Tata Medium Term Fund Segregated Portfolio 1 Direct Growth

Moderate Risk

-1.0%-187.2%
Tata Corporate Bond Fund Segregated Portfolio 1 Direct Growth

Moderate Risk

-0.0%-116.5%
TATA Nifty G-Sec Dec 2026 Index Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹110.25 Cr6.6%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk
Wealth Monitor

Unlock Expert Insights!

Maximise Returns with our Wealth Monitor App. Try it now!

Still got questions?
We're here to help.

The NAV of Tata India Pharma & Healthcare Fund Direct Growth, as of 17-May-2024, is ₹29.09.
The fund has generated 55.80% over the last 1 year and 17.72% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
The fund's allocation of assets is distributed as 97.69% in equities, 0.00% in bonds, and 2.31% in cash and cash equivalents.
The fund managers responsible for Tata India Pharma & Healthcare Fund Direct Growth are:-
  1. Meeta Shetty